Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine
Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine: Results From an 8-week, Multicenter, Double-blind, Placebo-controlled Trial
Sponsor: GlaxoSmithKline
Listed as NCT02989727, this PHASE4 trial focuses on Bipolar Depression and Bipolar Disorder and remains completed. Sponsored by GlaxoSmithKline, it has been updated 12 times since 2003, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE4
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE4
-
Mar 2019 — Nov 2020 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
-
Jan 2019 — Mar 2019 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE4
First recorded
Nov 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
- University of Saskatchewan
For direct contact, visit the study record on ClinicalTrials.gov .